Skip to main content

International Journal of Phytomedicine and Phytotherapy

Table 3 Clinical trials applying silymarin to patients with alcoholic liver disease

From: The potential of silymarin for the treatment of hepatic disorders

Study Silymarin Control Weighta WMD (fixed)
  N Mean (SD) N Mean (SD) % 95 % CI
DiMario et al., 1981 [70] 15 25.40 (15.60) 14 50.60 (24.30) 3.38 −25.20 [−40.18, −10.22]
Salmi et al., 1982 [71] 47 38.20(15.99) 50 51.20(24.99) 11 −13.00 [−21.30, −4.70]
Feher et al., 1989 [72] 17 22.80(5.10) 19 31.30(4.50) 76.01 −8.50 [−11.66, −5.34]
Müzes et al., 1990 [73] 10 28.00(11.00) 20 52.00(13.00) 9.6 −24.00 [−32.88, −15.12]
Total (95 % CI) 89   103   100 −11.05 [−13.80, −8.29]
  1. aWeighted mean differences of aspartate aminotransferase (AST) serum levels comparing control patients and patients receiving silymarin after the end of treatment
  2. Test for heterogeneity: Chi2 = 14.31, df = 3 (P = 0.003), I2 = 79.0 %
  3. Test for overall effect: Z = 7.86 (P < 0.00001)